Rocket


News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Immunocore Holdings plc (IMCR) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 144 Form 144 - Report of proposed sale of securities:
08/25/2023 144 Form 144 - Report of proposed sale of securities:
08/17/2023 144 Form 144 - Report of proposed sale of securities:
08/10/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Unaudited Condensed Consolidated Interim Financial Statements as at and for the Three and Six Months Ended June 30, 2023",
"Management’s Discussion and Analysis of Financial Condition and Results of Operations as at and for the Three and Six Months Ended June 30, 2023",
"Bahija Jallal, Chief Executive Officer of Immunocore",
"2Q 2023 1H 2023 KIMMTRAK"
07/14/2023 6-K Quarterly results
07/12/2023 144 Form 144 - Report of proposed sale of securities:
06/15/2023 SC 13D/A GENERAL ATLANTIC, L.P. reports a 5.9% stake in Immunocore Holdings plc
06/05/2023 144 Form 144 - Report of proposed sale of securities:
05/10/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Unaudited Condensed Consolidated Interim Financial Statements as at and for the Three Months Ended March 31, 2023",
"Management’s Discussion and Analysis of Financial Condition and Results of Operations as at and for the Three Months Ended March 31, 2023",
"Ralph Torbay, Head of Commercial of Immunocore"
05/08/2023 144 Form 144 - Report of proposed sale of securities:
04/19/2023 144 Form 144 - Report of proposed sale of securities:
04/18/2023 6-K Quarterly results
04/18/2023 6-K Quarterly results
04/17/2023 144 Form 144 - Report of proposed sale of securities:
04/17/2023 144 Form 144 - Report of proposed sale of securities:
04/06/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/10/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
03/02/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Company letter to the shareholders",
"Company letter to the shareholders"
03/01/2023 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
03/01/2023 6-K Quarterly results
02/22/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"David Berman, Head of R&D of Immunocore",
"Slides Added to Corporate Presentation"
02/14/2023 SC 13G/A Rock Springs Capital Management LP reports a 7.3% stake in Immunocore Holdings plc
02/14/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
01/17/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
01/11/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Annual J.P. Morgan Healthcare Conference presentation",
"Annual J.P. Morgan Healthcare Conference presentation"
01/09/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Cytokine Release Syndrome , which may be serious or life-threatening, occurred in patients receiving KIMMTRAK. Monitor for at least 16 hours following first three infusions and then as clinically indicated. Manifestations of CRS may include fever, hypotension, hypoxia, chills, nausea, vomiting, rash, elevated transaminases, fatigue, and headache. CRS occurred in 89% of patients who received KIMMTRAK with 0.8% being grade 3 or 4. Ensure immediate access to medications and resuscitative equipment to manage CRS. Ensure patients are euvolemic prior to initiating the infusions. Closely monitor patients for signs or symptoms of CRS following infusions of KIMMTRAK. Monitor fluid status, vital signs, and oxygenation level and provide appropriate therapy. Withhold or discontinue KIMMTRAK depending ...",
"Corporate Presentation",
"Pipeline Chart"
12/20/2022 SC 13D/A GENERAL ATLANTIC, L.P. reports a 9.6% stake in Immunocore Holdings plc
12/08/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Immunocore presents ovarian cancer expansion data for ImmTAC ® candidate IMC-C103C targeting MAGE-A4"
12/02/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta TCR ImmTAC for Solid Tumors"
11/18/2022 6-K/A Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]
11/09/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Unaudited Condensed Consolidated Interim Financial Statements for the Three and Nine Months Ended September 30, 2022",
"Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Three and Nine Months Ended September 30, 2022",
"commented Bahija Jallal, Chief Executive Officer of Immunocore.",
"Loan agreement, among Immunocore Limited, as Borrower, the Registrant, certain additional Credit Parties and Guarantors party thereto, BioPharma Credit PLC, as Collateral Agent, and BPCR Limited Partnership and BioPharma Credit Investments V (Master) LP as Lenders"
09/30/2022 6-K Quarterly results
09/30/2022 424B7 Form 424B7 - Prospectus [Rule 424(b)(7)]:
09/09/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Sales Agreement, by and between the Company and Jefferies LLC",
"Opinion of Cooley (UK) LLP",
"Recent Developments section of the Prospectus Supplement Summary included in the Company’s Prospectus Supplement to the Registration Statement on Form F-3ASR (File No. 333-264105)"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy